2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-172082
    MEP-FUBICA 2749985-70-2 98%
    MEP-FUBICA is structurally categorized as a synthetic cannabinoid.
    MEP-FUBICA
  • HY-172149
    Naltrindole 5′-isothiocyanate 126876-64-0 98%
    Naltrindole 5′-isothiocyanate (5'-NTII) is a non-selective delta opioid receptor antagonist that can antagonize the analgesic effects induced by DSLET (HY-P1332) without affecting the analgesic effects induced by DPDPE (HY-P1334).
    Naltrindole 5′-isothiocyanate
  • HY-172705
    DSPE-PEG2000-RVG29 98%
    DSPE-PEG2000-RVG29 is a PEG conjugate composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB), crosses the BBB, and mediates receptor-dependent transcytosis. DSPE-PEG2000-RVG29 can be used for brain-targeted drug delivery, surface modification of nanocarriers, as well as gene and nucleic acid delivery. DSPE-PEG2000-RVG29 is applicable to research related to hypoxic-ischemic brain injury, Parkinson's disease, and other conditions.
    DSPE-PEG2000-RVG29
  • HY-172751
    1(R)-Tetrahydrocannabidiol 3061058-81-6 98%
    1(R)-Tetrahydrocannabidiol (Compound 4) is a drug derivative that can be used in research on neurological diseases.
    1(R)-Tetrahydrocannabidiol
  • HY-172837
    3-Ethoxy-4-methoxy N,N-diethylhexedrone hydrochloride
    3-Ethoxy-4-methoxy N,N-diethylhexedrone hydrochloride is a drug analogue that can be used for neurological diseases research.
    3-Ethoxy-4-methoxy N,N-diethylhexedrone hydrochloride
  • HY-172844
    3-Ethoxy-4-methoxy N,N-diethylpentedrone hydrochloride
    3-Ethoxy-4-methoxy N,N-diethylpentedrone hydrochloride is a drug analogue that can be used in the research of mental disorders.
    3-Ethoxy-4-methoxy N,N-diethylpentedrone hydrochloride
  • HY-172845
    3-Methoxy-4-ethoxy N,N-diethylpentedrone hydrochloride
    3-Methoxy-4-ethoxy N,N-diethylpentedrone hydrochloride is a drug analogue, which can be used in the research of neurological diseases.
    3-Methoxy-4-ethoxy N,N-diethylpentedrone hydrochloride
  • HY-172846
    6-Methoxy-N,N-diethylpentylone hydrochloride
    6-Methoxy-N,N-diethylpentylone hydrochloride is an alkaloid derivative and can be used for the research of neurological disease.
    6-Methoxy-N,N-diethylpentylone hydrochloride
  • HY-172856
    Δ8-Iso-THC acetate
    Δ8-Iso-THC acetate is a phytocannabinoid analogue.
    Δ8-Iso-THC acetate
  • HY-172864
    AB-MDMSBA 98%
    AB-MDMSBA is a synthetic cannabinoid.
    AB-MDMSBA
  • HY-172867
    CH-HEXIATA
    CH-HEXIATA (CH-HIATA) is a drug derivative and can be used for the research of neurological disease.
    CH-HEXIATA
  • HY-173302
    sEH inhibitor-20 98%
    sEH inhibitor-20 is an orally active and metabolically stable sEH inhibitor (IC50: 0.2 nM). sEH inhibitor-20 has significant analgesic and anti-inflammatory activities and is expected to become a potential candidate compound for the study of neuropathic pain.
    sEH inhibitor-20
  • HY-17354A
    (R)-Baclofen hydrochloride 63701-55-3 98.12%
    (R)-Baclofen hydrochloride (Arbaclofen hydrochloride) is a selective GABAB receptor agonist.
    (R)-Baclofen hydrochloride
  • HY-17355R
    Pramipexole dihydrochloride (Standard) 104632-25-9 98%
    Pramipexole (dihydrochloride) (Standard) is the analytical standard of Pramipexole (dihydrochloride). This product is intended for research and analytical applications. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS).
    Pramipexole dihydrochloride (Standard)
  • HY-17357R
    Nepafenac (Standard) 78281-72-8 98%
    Nepafenac (AHR 9434; AL 6515) (Standard) is the analytical standard of Nepafenac (HY-17357). This product is intended for research and analytical applications. Nepafenac, a nonsteroidal anti-inflammatory agent, is a topically administered COX-2 inhibitor with an IC50 of 0.12 μM. Nepafenac exhibits only weak COX-1 inhibitory activity (IC50 = 64.3 μM). Nepafenac possesses unique prodrug properties, which enable it to rapidly convert into the active metabolite Amfenac (HY-17479) in the ocular tissues, thereby achieving high concentrations in the retina and choroid. Nepafenac reduces inflammation and pain by inhibiting the activity of cyclooxygenase (COX) enzymes and thereby decreasing the production of prostaglandin PGE₂. Nepafenac can delay the metastasis of uveal melanoma (UM) in rabbit eyes. Nepafenac is mainly used for pain management and inflammation control after ophthalmic surgeries.
    Nepafenac (Standard)
  • HY-173644
    3,4-Methylenedioxy pcp hydrochloride 98%
    3,4-Methylenedioxy pcp hydrochloride (3,4-MDPCP hydrochloride; 3,4-Methylenedioxy phencyclidine hydrochloride) is a drug derivative that can be used for research on mental illnesses.
    3,4-Methylenedioxy pcp hydrochloride
  • HY-17383A
    Levomefolate disodium 1423663-76-6 98%
    Levomefolate disodium is a synthetic disodium salt of L-5-methyltetrahydrofolate and an orally active and brain-penetrant folate supplement. Levomefolate disodium incorporates into body folate pools to increase plasma and red blood cell folate levels over time. Levomefolate disodium does not significantly increase folate concentrations in breast milk. Levomefolate disodium can be used for the research of neural tube defects and megaloblastic anemia.
    Levomefolate disodium
  • HY-17385R
    Atomoxetine hydrochloride (Standard) 82248-59-7 98%
    Atomoxetine (hydrochloride) (Standard) is the analytical standard of Atomoxetine (hydrochloride). This product is intended for research and analytical applications. Atomoxetine (Tomoxetine) hydrochloride is a selective noradrenaline reuptake inhibitor with Ki values of 5 nM, 77 nM and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine hydrochloride is a potent Na+ channels (VGSCs) blocker. Atomoxetine hydrochloride can be used for attention-deficit hyperactivity disorder (ADHD) research.
    Atomoxetine hydrochloride (Standard)
  • HY-17390R
    Loxapine (Standard) 1977-10-2 98%
    Loxapine (Standard) is the analytical standard of Loxapine. This product is intended for research and analytical applications. Loxapine is an orally active dopamine inhibitor, 5-HT receptor antagonist and also a dibenzoxazepine anti-psychotic agent.
    Loxapine (Standard)
  • HY-17407R
    Ziprasidone hydrochloride monohydrate (Standard) 138982-67-9
    Ziprasidone (hydrochloride monohydrate) (Standard) is the analytical standard of Ziprasidone (hydrochloride monohydrate). This product is intended for research and analytical applications. Ziprasidone (CP-88059) hydrochloride monohydrate is an orally active combined 5-HT and dopamine receptor antagonist. Ziprasidone hydrochloride monohydrate has affinities for Rat D2 (Ki=4.8 nM), 5-HT2A (Ki=0.42 nM) and 5-HT1A (Ki=3.4 nM).
    Ziprasidone hydrochloride monohydrate (Standard)
Cat. No. Product Name / Synonyms Application Reactivity